Welcome to the 7th Obesity & NASH Drug Development Summit, scheduled from Mon, 27 Nov 2023, at 09:25 to Wed, 29 Nov 2023, at 16:00. Eli Lilly's 'triple G' drug, retatrutide, revolutionizes obesity treatment with a groundbreaking 24% weight loss, igniting investment in the metabolic field. Simultaneously, Madrigal's THR β-selective agonist heralds the potential first approved NASH treatment, marking a pivotal era in metabolic drug development. This summit convenes industry experts to assess biomarkers for regulatory approval, delve into GLP-1 RAs with FGF21, GIP, Amylin, and glucagon receptors, and explore combination therapies for efficacy and safety. Join 160+ experts from leading pharmaceuticals to pave the way for innovative weight-loss drugs and the first NASH approval. 

[Read on obesity-and-nash-summit.com](https://obesity-and-nash-summit.com/)

Continue reading at obesity-and-nash-summit.com

Health and Wellness

Facebook Share

Twitter Share

Linkedin Share

Email Share